2018 American Society of Hematology Annual Meeting*

Hematology 2018 Conference Image
Download All
December 1-4, 2018; San Diego, California
Key leukemia abstracts selected by Keith Pratz, MD, and Farhad Ravandi, MD, presented at the 2018 ASH annual meeting.
Keith W. Pratz, MD
Farhad Ravandi, MD

Leukemias

Slidesets Phase I Study of IMGN779, a Novel CD33-Targeted ADC, in Relapsed/Refractory CD33+ Acute Myeloid Leukemia
Slidesets Phase II Trial of Sequential HCVAD With Blinatumomab as Frontline Therapy for Adults With Ph-Negative B-Cell ALL
Slidesets Phase II SWOG 1318: First-line Blinatumomab Followed by POMP Maintenance in Older Patients Newly Diagnosed With Ph-Negative B-Cell ALL
Slidesets Phase II Study: Inotuzumab Ozogamicin + Low-Intensity Chemo ± Blinatumomab in Newly Diagnosed Older Patients With Ph- ALL
Slidesets Generic vs Brand Name Imatinib for Untreated Chronic-Phase Chronic Myeloid Leukemia: Findings From an Observational Cohort Study
Slidesets Phase Ib Trial: Frontline Venetoclax + Decitabine or Azacitidine in Older Patients With Untreated AML Who Are Ineligible for Intensive Chemotherapy
Slidesets Long-term OS Follow-up of Phase II BLAST: Blinatumomab in Adults With Ph-Negative B-Cell Precursor ALL Who Are MRD Positive
Slidesets Ivosidenib or Enasidenib Plus Standard Induction and Consolidation Chemotherapy in Newly Diagnosed, IDH1/IDH2-Mutated AML
Slidesets QuANTUM-R: Phase III Trial of Quizartinib in Patients With FLT3-ITD–Mutated Relapsed/Refractory AML
Slidesets Phase I Study of Gilteritinib Combined With 7+3 Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia: Updated Results
Slidesets SORMAIN: Sorafenib vs Placebo Maintenance Therapy After Allogeneic SCT in FLT3-ITD AML

Gain expert insights on key studies on the management of acute and chronic leukemias presented at the Hematology 2018 annual meeting in San Diego.

Keith W. Pratz, MD Farhad Ravandi, MD Physicians: maximum of 3.0 AMA PRA Category 1 Credits™ Released: February 28, 2019 Expired: No longer available for credit
Provided by the Annenberg Center for Health Sciences at Eisenhower.
ACHS Logo
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Celgene Corporation
Dova Pharmaceuticals, Inc.
Gilead Sciences
Incyte
Jazz Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Seagen
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings